You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life ...

This new lineup prioritizes simplicity, effectiveness, and skin health for all ages, focusing on Generation Alpha and Gen Z.

Auron Therapeutics has raised a $27 million Series B financing that it will use to initiate clinical development of its lead experimental drug, AUTX-703, in blood cancers.